ロード中...
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
BACKGROUND: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-t...
保存先:
| 出版年: | J Transl Med |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4566296/ https://ncbi.nlm.nih.gov/pubmed/26357842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0644-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|